Abstract
The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance bioavailability through the improvement of dissolution rate and saturation solubility of drugs, by virtue of their small sizes. Nano-drugs available in the market are usually produced by top-down methods, such as wet milling and high pressure homogenization. These conventional top-down methods, however, suffer from high energy and time requirement, as well as wide and inconsistent nano-drug size distribution. Furthermore, commercially available nano-drugs are predominantly crystalline while amorphous nano-drugs are largely neglected despite their propensity to generate high saturation solubility. In this review, nonconventional methods to prepare crystalline and amorphous nano-drugs are discussed, with the bioavailability enhancing characteristics highlighted. Both top-down and bottom-up methods are covered, finally, a sustainability-based perspective comparing amorphous and crystalline nano-drugs is presented.
Keywords: Nanoparticle, nano-crystals, amorphous drug nanoparticles, bioavailability enhancement, top-down, bottom-up.
Current Pharmaceutical Design
Title:Towards Sustainability: New Approaches to Nano-Drug Preparation
Volume: 19 Issue: 35
Author(s): Wean Sin Cheow, Rong Xu and Kunn Hadinoto
Affiliation:
Keywords: Nanoparticle, nano-crystals, amorphous drug nanoparticles, bioavailability enhancement, top-down, bottom-up.
Abstract: The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance bioavailability through the improvement of dissolution rate and saturation solubility of drugs, by virtue of their small sizes. Nano-drugs available in the market are usually produced by top-down methods, such as wet milling and high pressure homogenization. These conventional top-down methods, however, suffer from high energy and time requirement, as well as wide and inconsistent nano-drug size distribution. Furthermore, commercially available nano-drugs are predominantly crystalline while amorphous nano-drugs are largely neglected despite their propensity to generate high saturation solubility. In this review, nonconventional methods to prepare crystalline and amorphous nano-drugs are discussed, with the bioavailability enhancing characteristics highlighted. Both top-down and bottom-up methods are covered, finally, a sustainability-based perspective comparing amorphous and crystalline nano-drugs is presented.
Export Options
About this article
Cite this article as:
Cheow Sin Wean, Xu Rong and Hadinoto Kunn, Towards Sustainability: New Approaches to Nano-Drug Preparation, Current Pharmaceutical Design 2013; 19 (35) . https://dx.doi.org/10.2174/1381612811319350002
DOI https://dx.doi.org/10.2174/1381612811319350002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Cytotoxicity Evaluation of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines Against Cancerous Liver Cells
Current Chemical Biology The Mouse In Cancer Research Past, Present, Future
Current Genomics Neoadjuvant Strategies for Triple Negative Breast Cancer: ‘State-of-the-art’ and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Cancer Metastasis Treatments
Current Drug Therapy Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges
Current Topics in Medicinal Chemistry Classification of Breast Cancer Resistant Protein (BCRP) Inhibitors and Non-Inhibitors Using Machine Learning Approaches
Combinatorial Chemistry & High Throughput Screening Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Exploring the Lapse in Druggability: Sequence Analysis, Structural Dynamics and Binding Site Characterization of K-RasG12C Variant, a Feasible Oncotherapeutics Target
Anti-Cancer Agents in Medicinal Chemistry Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile
Current Drug Safety A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry Breast Cancer Diagnosis in Digital Mammography Images Using Automatic Detection for the Region of Interest
Current Medical Imaging Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer
Mini-Reviews in Medicinal Chemistry Anticancer Drugs Aimed at E6 and E7 Activity in HPV-Positive Cervical Cancer
Current Cancer Drug Targets The Anterior Gradient-2 Pathway as a Model for Developing Peptide-Aptamer Anti-Cancer Drug Leads that Stimulate p53 Function
Current Chemical Biology Revision of the Regioselectivity of the Beirut Reaction of Monosubstituted Benzofuroxans with Benzoylacetonitrile. 6-Substituted quinoxaline-2-carbonitrile 1,4- dioxides: Structural Characterization and Estimation of Anticancer Activity and Hypoxia Selectivity
Current Organic Synthesis Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery